Current Cardiology Reviews最新文献_第3页

Pro- and Anti-inflammatory Biomarkers Responses after Aerobic Training in Heart Transplant Recipients: A Systematic Review and Meta-analysis. 心脏移植受者有氧训练后的促炎和抗炎生物标志物反应：系统回顾与元分析》。

IF 1.9

Current Cardiology Reviews Pub Date : 2024-04-02 DOI: 10.2174/011573403X269909240320061952

L. Franzoni, Stephanie Bastos da Motta, Gabriel Carvalho, Rochelle Rocha Costa, M. M. Ahner, M. Saffi, A. A. Pereira, A. H. Pereira, A. D. da Silveira, Ricardo Stein

{"title":"Pro- and Anti-inflammatory Biomarkers Responses after Aerobic Training in Heart Transplant Recipients: A Systematic Review and Meta-analysis.","authors":"L. Franzoni, Stephanie Bastos da Motta, Gabriel Carvalho, Rochelle Rocha Costa, M. M. Ahner, M. Saffi, A. A. Pereira, A. H. Pereira, A. D. da Silveira, Ricardo Stein","doi":"10.2174/011573403X269909240320061952","DOIUrl":"https://doi.org/10.2174/011573403X269909240320061952","url":null,"abstract":"BACKGROUND\u0000Physical exercise (PE) may improve plasma concentration of interleukin- 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and adiponectin (adpN) in heart transplant (HT) patients. However, no consistent data is available on this population.\u0000\u0000\u0000AIM\u0000Thus, we aimed to conduct a systematic review and meta-analysis on the effects of PE over these pro- and anti-inflammatory biomarkers in HT patients.\u0000\u0000\u0000METHODS\u0000Following the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement, we conducted a systematic literature search in the PubMed, Cochrane, and Scopus databases. Outcomes included IL-6, TNF-alpha, and adpN. Effect size (ES) was calculated using the standardized mean difference with a 95% confidence interval (CI).\u0000\u0000\u0000RESULTS\u0000The PE group (aerobic modality) was associated with reduced IL-6 compared to the control group (ES: -0.53; 95% CI: -0.99 to -0.06 pg/mL; P = 0.026). However, the PE group did not show a significant effect on TNF-alpha and adpN levels (ES: -0.33; 95% CI: -0.79 to 0.13; P = 0.16 and ES: -0.20; 95% CI: -0.70 to 0.30 pg/mL; P = 0.444, respectively).\u0000\u0000\u0000CONCLUSION\u0000PE is associated with IL-6 reductions, although TNF alpha and adpN did not change after this intervention in HT patients. Therefore, PE is an effective intervention to downregulate IL-6 in post-HT patients.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140754251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Symptoms, Dysautonomia, and Quality of Life in Adult and Pediatric Patients with Hypermobile Ehlers-Danlos Syndrome: A Brief Review. 高移动性埃勒斯-丹洛斯综合征成人和儿童患者的心血管症状、自主神经功能障碍和生活质量：简要回顾

IF 1.9

Current Cardiology Reviews Pub Date : 2024-01-24 DOI: 10.2174/011573403X271096231203164216

Amanda Hertel, William R Black, Lindsey Malloy Walton, Julie Martin, Jordan Jones

{"title":"Cardiovascular Symptoms, Dysautonomia, and Quality of Life in Adult and Pediatric Patients with Hypermobile Ehlers-Danlos Syndrome: A Brief Review.","authors":"Amanda Hertel, William R Black, Lindsey Malloy Walton, Julie Martin, Jordan Jones","doi":"10.2174/011573403X271096231203164216","DOIUrl":"10.2174/011573403X271096231203164216","url":null,"abstract":"Background: Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by joint hypermobility and other systemic manifestations, such as cardiovascular symptoms, musculoskeletal pain, and joint instability. Cardiovascular symptoms, such as lightheadedness and palpitations, and types of dysautonomia, including postural orthostatic tachycardia syndrome (POTS), are frequently reported in adults with hEDS and have been shown to negatively impact quality of life (QoL).Objective: This brief review will be an overview of co-occurring symptoms in POTS and hEDS to inform potential cardiovascular screening procedures.Results: While many patients with hEDS report cardiovascular symptoms, few have structural abnormalities, suggesting that dysautonomia is likely responsible for these symptoms. One validated screening measure for dysautonomia symptom burden is the Composite Autonomic Symptom Scale (COMPASS-31). Studies have found that adults with POTS, hEDS, and both POTS and hEDS have higher COMPASS-31 scores than the general population, suggesting a high symptom burden due to dysautonomia, which leads to impaired QoL.Conclusion: While studies have examined cardiovascular symptoms and the impact of dysautonomia in adults with and without hEDS, there is scant literature on dysautonomia in pediatric patients with hEDS. Therefore, more studies on cardiovascular symptoms and dysautonomia, as they relate to the quality of life in pediatric patients with hEDS, are needed. This brief review summarizes the current literature on dysautonomia and cardiovascular symptoms in pediatric and adult populations with hEDS.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139564008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Strategies to Improve the Cardioprotective Effects of Cardioplegia. 改善心脏麻痹对心脏保护作用的新策略

IF 1.9

Current Cardiology Reviews Pub Date : 2024-01-24 DOI: 10.2174/011573403X263956231129064455

Estefanie Osorio-Llanes, Jairo Castellar-López, Wendy Rosales-Rada, Yulieth Montoya, John Bustamante, Ricardo Zalaquett, Roberto Bravo-Sagua, Jaime A Riquelme, Gina Sánchez, Mario Chiong, Sergio Lavandero, Evelyn Mendoza-Torres

{"title":"Novel Strategies to Improve the Cardioprotective Effects of Cardioplegia.","authors":"Estefanie Osorio-Llanes, Jairo Castellar-López, Wendy Rosales-Rada, Yulieth Montoya, John Bustamante, Ricardo Zalaquett, Roberto Bravo-Sagua, Jaime A Riquelme, Gina Sánchez, Mario Chiong, Sergio Lavandero, Evelyn Mendoza-Torres","doi":"10.2174/011573403X263956231129064455","DOIUrl":"10.2174/011573403X263956231129064455","url":null,"abstract":"The use of cardioprotective strategies as adjuvants of cardioplegic solutions has become an ideal alternative for the improvement of post-surgery heart recovery. The choice of the optimal cardioplegia, as well as its distribution mechanism, remains controversial in the field of cardiovascular surgery. There is still a need to search for new and better cardioprotective methods during cardioplegic procedures. New techniques for the management of cardiovascular complications during cardioplegia have evolved with new alternatives and additives, and each new strategy provides a tool to neutralize the damage after ischemia/reperfusion events. Researchers and clinicians have committed themselves to studying the effect of new strategies and adjuvant components with the potential to improve the cardioprotective effect of cardioplegic solutions in preventing myocardial ischemia/reperfusion-induced injury during cardiac surgery. The aim of this review is to explore the different types of cardioplegia, their protection mechanisms, and which strategies have been proposed to enhance the function of these solutions in hearts exposed to cardiovascular pathologies that require surgical alternatives for their corrective progression.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139564011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac Axis in Early Gestation and Congenital Heart Disease. 妊娠早期的心轴与先天性心脏病

IF 1.9

Current Cardiology Reviews Pub Date : 2024-01-24 DOI: 10.2174/011573403X264660231210162041

D Carrasco, L Guedes-Martins

引用次数: 0

Physiological Evidence and Therapeutic Outcomes of Vitamin D on Cardiovascular Diseases. 维生素 D 对心血管疾病的生理证据和治疗效果。

IF 1.9

Current Cardiology Reviews Pub Date : 2024-01-18 DOI: 10.2174/011573403X263417231107110618

Abolfazl Zendehdel, Amir Shakarami, Ehsan Sekhavati Moghadam

引用次数: 0

Understanding the Role of Galectin-1 in Heart Failure: A Comprehensive Narrative Review. 了解 Galectin-1 在心力衰竭中的作用：全面叙述性综述。

IF 1.9

Current Cardiology Reviews Pub Date : 2024-01-08 DOI: 10.2174/011573403X274886231227111902

Mohammad Javad Sotoudeheian, Seyed-Mohamad-Sadegh Mirahmadi, Mohammad Pirhayati, Reza Azarbad, Soroush Nematollahi, Mehdi Taghizadeh, Hamidreza Pazoki-Toroudi

{"title":"Understanding the Role of Galectin-1 in Heart Failure: A Comprehensive Narrative Review.","authors":"Mohammad Javad Sotoudeheian, Seyed-Mohamad-Sadegh Mirahmadi, Mohammad Pirhayati, Reza Azarbad, Soroush Nematollahi, Mehdi Taghizadeh, Hamidreza Pazoki-Toroudi","doi":"10.2174/011573403X274886231227111902","DOIUrl":"10.2174/011573403X274886231227111902","url":null,"abstract":"Heart failure (HF) is the fastest-growing cardiovascular condition worldwide. The immune system may play a role in the development of HF since this condition is associated with elevated pro-inflammatory cytokine levels. HF is a life-threatening disease, and there is an increasing demand for diagnostic biomarkers, prognostic factors, and therapeutic agents that can help treat it. Galectin-1 (Gal-1) is the prototype galectin of the lectin family. Multiple signal transduction pathways are regulated by Ras proteins, which act as a molecular switch in cells. Gal-1 regulates T and B cell activation, differentiation, and survival. Gal-1 has been linked to inflammation. Activated T cells produce Gal-1 through an autocrine apoptotic mechanism involving MEK1/ERK and p38 MAPK. In the cardiovascular system, atherosclerosis is facilitated by Gal-1. Heart disease, myocardial infarction, hypertension, and stroke can be caused by atherosclerotic plaque. HF and heart hypertrophy are caused by decreased cardiac L-type Ca2+ channel activity. Deregulation of Gal-1 and CaV1.2 in pathological cardiac hypertrophy suggests a possible target for anti-hypertrophic therapy. Rat hypertrophic cardiomyocytes express Gal-1 and CaV1.2 channels simultaneously. It has been reported that diastolic dysfunction (DD) is associated with elevated Gal-1 levels. The high Gal-1 level in subjects led to the lowest cumulative survival as a composite endpoint. Incidences of HF, DD, and serum Gal-1 levels correlated significantly. The ejection fraction was negatively correlated with Gal-1 and CRP concentrations. Based on two different approaches in mice and humans, Gal-1 was identified as a potential mediator of HF.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Nutrients and Cardiovascular Diseases. 营养素与心血管疾病之间的关系。

IF 1.9

Current Cardiology Reviews Pub Date : 2024-01-05 DOI: 10.2174/011573403X263414231101095310

Amir Shakarami

引用次数: 0

Percutaneous Patent Foramen Ovale Closure: Stroke and Beyond. 经皮闭孔器：中风及其他。

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-01 DOI: 10.2174/011573403X276984240304044109

Sandeep Randhawa, Jawahar L Mehta, Gaurav Dhar

{"title":"Percutaneous Patent Foramen Ovale Closure: Stroke and Beyond.","authors":"Sandeep Randhawa, Jawahar L Mehta, Gaurav Dhar","doi":"10.2174/011573403X276984240304044109","DOIUrl":"10.2174/011573403X276984240304044109","url":null,"abstract":"Over 750,000 individuals suffer from stroke annually in the United States, with 87% of these strokes being ischemic in nature. Roughly 40% of ischemic strokes occur in individuals 60 years of age or under. A quarter of all ischemic strokes have no identifiable cause despite extensive workup and are deemed cryptogenic in nature. Patent Foramen Ovales (PFO) has been postulated in stroke causation by either paradoxical embolization or platelet activation in the tunnel of the defect. The incidence of PFO is reported to be 15-25% in the general population but rises to 40% in patients with cryptogenic stroke. While the initial trials evaluating PFO closures were non-revealing, subsequent long-term follow-ups, as well as recent trials evaluating PFO closures in cryptogenic stroke patients 60 years of age or under, demonstrated the superiority of percutaneous closure compared to medical therapy alone, leading to FDA approval of PFO closure devices. In this review, we review the diagnosis of PFO, postulated stroke mechanisms, literature supporting PFO closure, patient selection for percutaneous closure, procedural considerations, and associated procedural complications.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140130959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aldosterone Effect on Cardiac Structure and Function. 醛固酮对心脏结构和功能的影响

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-01 DOI: 10.2174/011573403X281390240219063817

Ekhlas Mahmoud Al-Hashedi, Fuad A Abdu

{"title":"Aldosterone Effect on Cardiac Structure and Function.","authors":"Ekhlas Mahmoud Al-Hashedi, Fuad A Abdu","doi":"10.2174/011573403X281390240219063817","DOIUrl":"10.2174/011573403X281390240219063817","url":null,"abstract":"Background: Cardiac remodelling could be a key mechanism in aldosteronemediated cardiovascular morbidity and mortality. Experimental and clinical evidence has demonstrated that aldosterone causes cardiac structural remodelling and dysfunction by its profibrotic and pro-hypertrophic effects, which result mainly from the direct effects on myocardial collagen deposition, inflammation, and oxidative stress. Clinical studies have investigated the aldosterone effects on the heart in different clinical conditions, including general population, essential hypertension, primary aldosteronism, heart failure, and atrial fibrillation. Robust findings indicate that aldosterone or the activation of the cardiac mineralocorticoid receptor can cause damage to myocardial tissue by mechanisms independent of the blood pressure, leading to tissue hypertrophy, fibrosis, and dysfunction.Conclusion: Aldosterone-mediated cardiovascular morbidity and mortality mainly result from cardiac structural and functional alterations. In different clinical settings, aldosterone can induce cardiac structural remodelling and dysfunction via several pathological mechanisms, including cardiac fibrosis, inflammation, and oxidative stress. Aldosterone antagonists could effectively decrease or reverse the detrimental aldosterone-mediated changes in the heart.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological Triggers of Takotsubo Cardiomyopathy: An Updated Review of Evidence and Recommendations. 塔克苏博心肌病的药理诱因：证据和建议的最新回顾。

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-01 DOI: 10.2174/011573403X273613240125072754

S Arunkumar, K Jegaverrapandi

{"title":"Pharmacological Triggers of Takotsubo Cardiomyopathy: An Updated Review of Evidence and Recommendations.","authors":"S Arunkumar, K Jegaverrapandi","doi":"10.2174/011573403X273613240125072754","DOIUrl":"10.2174/011573403X273613240125072754","url":null,"abstract":"Background: Previous publications in 2011, 2016, and 2022 have presented lists of drugs associated with takotsubo cardiomyopathy (TCM). This review aims to provide updated drug lists that have been reported as potential causes of TCM.Methods: Following the same methodology employed in previous reviews, a detailed investigation was carried out in the PubMed/Medline database from June 2022 to July 2023 to identify drug-induced TCM (DITC) case reports. Various search terms related to the drug-induced transient left ventricular ballooning syndrome, ampulla cardiomyopathy, apical ballooning syndrome, drug-induced broken heart syndrome, drug triggered takotsubo cardiomyopathy, takotsubo cardiomyopathy, and iatrogenic takotsubo cardiomyopathy were utilized. Filters for fulltext availability, case reports, human studies, and English language were applied. Articles reporting drugs associated with TCM development were included in the analysis.Results: Foremost 192 case reports were initially identified, with 75 drugs meeting the inclusion criteria after a thorough review. The latest revision identified seven drugs that might lead to TCM, with four drugs (57.14%) already reported in previous reviews and three drugs (42.86%) newly identified. Consequently, the updated drug list potentially triggering TCM in 2023 comprises a sum of 75 drugs.Conclusion: The recent 75 drugs provided additional evidence linking to TCM development. The updated list predominantly includes drugs that induce sympathetic overstimulation, although some drugs on the list have unclear associations with sympathetic nervous system activation.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11107468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139897941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0